招银国际发表研究报告指，石药集团(01093.HK) 去年总收入按年跌7.8%至290亿元人民币，其中已宗成药品销售按年跌7.4%至237亿元人民币。管理层预料，今年肿瘤药物销售额将进一步降至30亿元人民币；即使继续出现不利因，公司预料今年新产品销售额达约15亿元人民币，并目标今年有机收入呈正面增长。
该行料，集团今年及明年收入分别按年升1.6%及0.6%，各年盈利则分别按年升3.5%及5.5%，其目标价由5.97元下调至5.71元，维持其评级为“买入”。(ca/w)
(港股报价延迟最少十五分钟。沽空资料截至 2025-04-02 12:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.